VXRT
| Market cap | $156.19M |
|---|---|
| Enterprise value | $115.40M |
| Revenue | $8.885M |
|---|---|
| EBITDA | -$73.11 |
| Income | -$81.74 |
| Revenue Q/Q | 223.11% |
| Revenue Y/Y | N/A |
| P/E | N/A |
|---|---|
| Forward P/E | -1.05 |
| EV/Sales | 12.99 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 17.58 |
| P/FCF | N/A |
| Price/Book | 2.70 |
| Book/Share | 0.25 |
| Cash/Share | 0.17 |
| FCF yield | -43.43% |
| Volume | 34.185M / 1.327M |
|---|---|
| Relative vol. | 25.76 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 76.92% |
| Est. EPS Q/Q | 71.43% |
| Profit margin | -1,117.56% |
|---|---|
| Oper. margin | -921.16% |
| Gross margin | 100.00% |
| EBIT margin | -916.88% |
| EBITDA margin | -822.80% |
| Ret. on assets | -79.98% |
|---|---|
| Ret. on equity | -121.06% |
| ROIC | -66.92% |
| ROCE | -109.27% |
| Debt/Equity | 0.59 |
|---|---|
| Net debt/EBITDA | 1.63 |
| Current ratio | 3.14 |
| Quick ratio | 3.14 |
| Volatility | 12.04% |
|---|---|
| Beta | 1.08 |
| RSI | 42.59 |
|---|
| Insider ownership | 0.83% |
|---|---|
| Inst. ownership | 36.27% |
| Shares outst. | 176.838M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 20.83% |
| Short ratio | 7.44 |
| Dividend | $0.00 |
|---|---|
| Dividend yield | 0.00% |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 1 Aug 2024 |
Saturday, 5 August 2023
|
|
| Vaxart, Inc. Q2 2023 Earnings Call Transcript | |
Tuesday, 25 October 2022
|
|
| 3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street | |
Friday, 20 May 2022
|
|
| Vaxart Has Great News if You’re Afraid of Covid-19 — And You’re a Hamster | |
Wednesday, 18 May 2022
|
|
| These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall Street | |
Monday, 16 May 2022
|
|
| Can This 1 Thing Hurt Vaxart? | |
Wednesday, 4 May 2022
|
|
| Vaccine Makers Slump as Moderna, Pfizer Leave Full-Year Guidance Intact | |
Thursday, 14 April 2022
|
|
| 3 Biotech Stocks That Could Help Make You a Fortune | |
Thursday, 7 April 2022
|
|
| 3 of the Fastest-Growing Stocks on the Planet Through 2026 | |
Wednesday, 6 April 2022
|
|
| 3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall Street | |
Tuesday, 29 March 2022
|
|
| 10 Best Biotech Stocks Under $5 | |
Saturday, 26 March 2022
|
|
| Is Vaxart the Next Moderna? | |
| 3 No-Brainer Stocks to Buy Right Now for Less Than $6 | |
Thursday, 24 March 2022
|
|
| Is It Too Late to Buy Vaxart Stock? | |
Thursday, 24 February 2022
|
|
| Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates - Yahoo Finance | |
Wednesday, 23 February 2022
|
|
| These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge | |
Saturday, 29 January 2022
|
|
| Does Vaxart's Oral COVID Vaccine Have a Chance? | |
| 4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street | |
Thursday, 27 January 2022
|
|
| Could Vaxart's Vaccine Pill Help to End the Pandemic? | |
| 4 of the Fastest-Growing Stocks on the Planet in 2022 | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| W. Mark Watson Director | Buy 28 Dec 2022 | $15,200 |
| Robert A. Yedid Director | Option 19 Aug 2022 | $24,666 |
| Fuad Ahmad Interim CFO | Buy 22 Jun 2022 | $16,100 |
| Sean Tucker SVP and Chief Scientific Officer | Option 22 Apr 2022 | $30,800 |
| Robert A. Yedid Director | Sale 10 Jan 2022 | $9,015 |
| Margaret Echerd SVP and Principal Accntng Officer | Option 30 Nov 2021 | $5,691 |
| Margaret Echerd SVP and Principal Accntng Officer | Option 10 Sep 2021 | $2,864 |
| Sean Tucker SVP and Chief Scientific Officer | Sale 10 Aug 2021 | $102,000 |
| Margaret Echerd SVP and Principal Accntng Officer | Option 10 Aug 2021 | $2,846 |
| Margaret Echerd SVP and Principal Accntng Officer | Option 19 Jul 2021 | $2,844 |
| Michael J. Finney Director | Option 18 Jun 2021 | $14,756 |
Powered by
Robintrack.
Price target
Current $0.76
Average $17.67
Low $16
High $20
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.00% | Growth period | N/A |
| Last dividend date | Yield 3 years | 0.00% | Growth 3 years | +0.00% | |
| Last dividend | Yield 5 years | 0.00% | Growth 5 years | +0.00% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Wouter Latour (61) Chairman of the Board since 2020 | 61 | 2020 | $747,711 |
| Cezar Andrei Floroiu M.B.A. (48) CEO, Pres, Principal Financial Officer, and Director | 48 | $538,149 | |
| Dr. Sean N. Tucker (53) Sr. VP and Chief Scientific Officer | 53 | $530,720 | |
| Margaret A. Echerd (62) Sr. VP and Principal Accounting Officer | 62 | $523,068 | |
| Sean Tucker | 2018 | $435,908 | |
| Margaret Echerd (60) Principal Accounting Officer, Vice President, and Controller since 2019 | 60 | 2019 | $328,952 |
| Anne VanLent (72) Independent Director since 2013 | 72 | 2013 | $70,571 |
| Michael Finney (61) Independent Director since 2018 | 61 | 2018 | $58,411 |
| Robert Yedid (62) Lead Independent Director since 2019 | 62 | 2019 | $22,309 |
| Todd Davis (59) Independent Director since 2019 | 59 | 2019 | $20,461 |
| Karen Wilson (57) Independent Director since 2020 | 57 | 2020 | |
| Keith Maher (53) Director since 2019 | 53 | 2019 | |
| Steven Boyd (39) Director since 2019 | 39 | 2019 | |
| Andrei Floroiu (47) Chief Executive Officer, Principal Financial Officer, and Director since 2020 | 47 | 2020 | |
| Edward B. Berg | |||
| John M. Harland M.B.A., CPA (69) Consultant | 69 | ||
| Dr. James F. Cummings M.D. | |||
| Dr. Rajesh Kapoor Ph.D. | |||
| Dr. Richard M. Schwartz | |||
| Brant Biehn | |||
| Shaily Jaini Garg |
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
- Health Care > Biotechnology
- Vaxart Inc, 170 Harbor Way, South San Francisco 94080, United States
- 650 550 3500
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.00% | Growth period | N/A |
| Last dividend date | Yield 3 years | 0.00% | Growth 3 years | +0.00% | |
| Last dividend | Yield 5 years | 0.00% | Growth 5 years | +0.00% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $26.735 | $34.755 | |||
| Short term investments | $9.929 | $4.958 | |||
| Net receivables | $0.556 | $3.008 | |||
| Inventory | |||||
| Total current assets | $44.284 | $45.536 | |||
| Long term investments | |||||
| Property, plant & equipment | $34.855 | $36.571 | |||
| Goodwill & intangible assets | $8.614 | $8.797 | |||
| Total noncurrent assets | $44.386 | $46.294 | |||
| Total investments | $9.929 | $4.958 | |||
| Total assets | $88.67 | $91.83 | |||
| Current liabilities | |||||
| Accounts payable | $3.978 | $1.584 | |||
| Deferred revenue | |||||
| Short long term debt | $2.799 | $2.703 | |||
| Total current liabilities | $14.117 | $13.724 | |||
| Long term debt | $16.691 | $17.385 | |||
| Total noncurrent liabilities | $18.863 | $20.301 | |||
| Total debt | $19.49 | $20.088 | |||
| Total liabilities | $32.98 | $34.025 | |||
| Stockholders' equity | |||||
| Retained earnings | -$433.991 | -$409.574 | |||
| Other stockholder equity | -$0.01 | -$0.001 | |||
| Total stockholder equity | $55.69 | $57.805 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.755 | $46.013 | ||
| Short term investments | $4.958 | $49.704 | ||
| Net receivables | $3.008 | $0.02 | ||
| Inventory | ||||
| Total current assets | $45.536 | $99.451 | ||
| Long term investments | ||||
| Property, plant & equipment | $36.571 | $41.3 | ||
| Goodwill & intangible assets | $8.797 | $9.528 | ||
| Total noncurrent assets | $46.294 | $54.396 | ||
| Total investments | $4.958 | $49.704 | ||
| Total assets | $91.83 | $153.847 | ||
| Current liabilities | ||||
| Accounts payable | $1.584 | $5.514 | ||
| Deferred revenue | $2 | |||
| Short long term debt | $2.703 | $2.228 | ||
| Total current liabilities | $13.724 | $17.921 | ||
| Long term debt | $17.385 | $19.477 | ||
| Total noncurrent liabilities | $20.301 | $25.329 | ||
| Total debt | $20.088 | $21.705 | ||
| Total liabilities | $34.025 | $43.25 | ||
| Stockholders' equity | ||||
| Retained earnings | -$409.574 | -$327.109 | ||
| Other stockholder equity | -$0.001 | -$0.299 | ||
| Total stockholder equity | $57.805 | $110.597 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $2.181 | $3.245 | |||
| Cost of revenue | |||||
| Gross profit | $2.181 | $3.245 | |||
| Operating activities | |||||
| Research & development | $19.013 | $14.705 | |||
| Selling, general & administrative | $7.238 | $5.44 | |||
| Total operating expenses | $26.251 | $20.145 | |||
| Operating income | -$24.07 | -$16.9 | |||
| Income from continuing operations | |||||
| EBIT | -$24.372 | -$17.201 | |||
| Income tax expense | $0.045 | $0.174 | |||
| Interest expense | |||||
| Net income | |||||
| Net income | -$24.417 | -$17.375 | |||
| Income (for common shares) | -$24.417 | -$17.375 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.379 | $0.107 | ||
| Cost of revenue | ||||
| Gross profit | $7.379 | $0.107 | ||
| Operating activities | ||||
| Research & development | $68.142 | $81.054 | ||
| Selling, general & administrative | $22.584 | $29.386 | ||
| Total operating expenses | $90.726 | $114.694 | ||
| Operating income | -$83.347 | -$114.587 | ||
| Income from continuing operations | ||||
| EBIT | -$82.204 | -$107.691 | ||
| Income tax expense | $0.261 | $0.067 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$82.465 | -$107.758 | ||
| Income (for common shares) | -$82.465 | -$107.758 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$24.417 | -$17.375 | |||
| Operating activities | |||||
| Depreciation | $2.177 | $2.331 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $4.116 | $3.715 | |||
| Total cash flows from operations | -$21.191 | -$13.521 | |||
| Investing activities | |||||
| Capital expenditures | -$0.131 | $0.104 | |||
| Investments | -$4.893 | $15 | |||
| Total cash flows from investing | -$5.024 | $15.104 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $18.377 | $0.261 | |||
| Net borrowings | |||||
| Total cash flows from financing | $18.195 | -$0.066 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$8.02 | $1.517 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$82.465 | -$107.758 | ||
| Operating activities | ||||
| Depreciation | $8.624 | $5.805 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.132 | $13.587 | ||
| Total cash flows from operations | -$70.453 | -$94.779 | ||
| Investing activities | ||||
| Capital expenditures | -$1.751 | -$9.601 | ||
| Investments | $45.703 | -$10.814 | ||
| Total cash flows from investing | $43.952 | -$20.415 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.609 | $17.462 | ||
| Net borrowings | ||||
| Total cash flows from financing | $15.243 | $17.462 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$11.258 | -$97.732 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Ra Capital Management, L.P. |
Opened
|
15,384,615 | $20,000,000 |
| 2024 Q1 | Goldman Sachs Group Inc |
Opened
|
1,498,564 | $1,948,133 |
| 2024 Q1 | Qube Research & Technologies Ltd |
+32,840.39%
|
697,348 | $906,552 |
| 2024 Q1 | Marshall Wace, LL.P. |
Opened
|
533,079 | $693,003 |
| 2024 Q1 | Hrt Financial L.P. |
Opened
|
529,578 | $688 |
| 2024 Q1 | Gsa Capital Partners LL.P. |
-77.49%
|
109,976 | $143 |
| 2024 Q1 | Citigroup Inc |
+8,362,300.00%
|
250,872 | $326,134 |
| 2024 Q1 | Jpmorgan Chase & Co |
+27,138.00%
|
122,571 | $159,342 |
| 2024 Q1 | State Street Corp |
+25.12%
|
583,745 | $758,869 |
| 2024 Q1 | Morgan Stanley |
-24.84%
|
278,271 | $361,754 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Ra Capital Management, L.P. | 8.70% | 15,384,615 | |
| Vanguard Group Inc | 3.93% | 6,956,840 | |
| Geode Capital Management | 1.11% | 1,962,033 | |
| Blackrock | 1.00% | 1,774,346 | |
| Goldman Sachs Group Inc | 0.85% | 1,498,564 | |
| Citadel Advisors | 0.82% | 1,442,056 | |
| Qube Research & Technologies Ltd | 0.39% | 697,348 | |
| State Street Corp | 0.33% | 583,745 | |
| Marshall Wace, LL.P. | 0.30% | 533,079 | |
| Hrt Financial L.P. | 0.30% | 529,578 |
Sign up